{
    "id": "6027446d1cb411341a0000dd",
    "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the properties and effects of trimetazidine. Trimetazidine is a drug that is used to treat angina pectoris and is known to have a unique mechanism of action. It works by shifting myocardial metabolism from fatty acid oxidation to more efficient glucose oxidation, which can help reduce myocardial oxygen demand. However, the provided documents do not explicitly state that trimetazidine protects from myocardial injury after percutaneous coronary intervention (PCI). Let\\u2019s examine the provided options and documents to find the correct answer.\\n\\nTrimetazidine is a metabolic modulator that has been shown to have a positive effect on angina symptoms in patients with coronary artery disease. However, the provided documents do not provide direct evidence that trimetazidine protects from myocardial injury after PCI. In fact, document [5] mentions that trimetazidine may cause QT interval prolongation, which could potentially increase the risk of arrhythmias.\\n\\nBased on the information available, it appears that trimetazidine may not provide protection from myocardial injury after PCI, and its use may even increase the risk of certain adverse effects.\\n\\nTherefore, the correct answer is:\\n\\nB. no\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_1213",
            "title": "Pharmacology_Katzung",
            "content": "Perhexiline was found to benefit some patients with angina decades ago but was abandoned because of reports of hepatotoxicity and peripheral neuropathy. However, pharmacokinetic studies suggested that toxicity was due to variable clearance of the drug, with extremely high plasma concentrations in patients with deficient CYP2D6 activity. This drug may shift myocardial metabolism from fatty acid oxidation to more efficient glucose oxidation (compared with trimetazidine). Because it does not involve vasodilation, it may be useful in patients refractory to ordinary medical therapy if plasma concentration is carefully controlled. Perhexiline is currently approved in only a few countries (not the USA)."
        },
        {
            "id": "Pharmacology_Katzung_3806",
            "title": "Pharmacology_Katzung",
            "content": "The paradigm shift in 1980 on the causation of acute myo-cardial infarction to acute coronary occlusion by a thrombus created the rationale for thrombolytic therapy of this com-mon lethal disease. At that time\u2014and for the first time\u2014 intravenous thrombolytic therapy for acute myocardial infarction in the European Cooperative Study Group trial was found to reduce mortality. Later studies, with thousands of patients in each trial, provided enough statistical power for the 20% reduction in mortality to be considered statisti-cally significant. Although the standard of care in areas with adequate facilities and experience in percutaneous coronary intervention (PCI) now favors catheterization and placement of a stent, thrombolytic therapy is still very important where PCI is not readily available. The proper selection of patients for thrombolytic therapy is critical. The diagnosis of acute myocardial infarction is made clinically and is confirmed by electrocardiography. Patients with"
        },
        {
            "id": "InternalMed_Harrison_628",
            "title": "InternalMed_Harrison",
            "content": "RISK ModIFICATIoN: PREVENTIVE STRATEgIES To REdUCE CARdIAC RISK Perioperative Coronary Revascularization Currently, potential options for reducing perioperative cardiovascular risk include coronary artery revascularization and/or perioperative preventive medical therapies (Chap. 293). Prophylactic coronary revascularization with either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) provides no shortor midterm survival benefit for patients without left main CAD or three-vessel CAD in the presence of poor left ventricular systolic function and is not recommended for patients with stable CAD before noncardiac surgery. Although PCI is associated with lower procedural risk than is CABG in the perioperative setting, the placement of a coronary artery stent soon before noncardiac surgery may increase the risk of bleeding during surgery if dual antiplatelet therapy (aspirin and thienopyridine) is administered; moreover, stent placement shortly before"
        },
        {
            "id": "Pharmacology_Katzung_3807",
            "title": "Pharmacology_Katzung",
            "content": "The proper selection of patients for thrombolytic therapy is critical. The diagnosis of acute myocardial infarction is made clinically and is confirmed by electrocardiography. Patients with ST-segment elevation and bundle branch block on electrocardi-ography have the best outcomes. All trials to date show the great-est benefit for thrombolytic therapy when it is given early, within 6 hours after symptomatic onset of acute myocardial infarction. Thrombolytic drugs reduce the mortality of acute myocardial infarction. The early and appropriate use of any thrombolytic drug probably transcends possible advantages of a particular drug."
        },
        {
            "id": "InternalMed_Harrison_19280",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 295-4 Reperfusion therapy for patients with ST-segment elevation myocardial infarction (STEMI). The bold arrows and boxes are the preferred strategies. Performance of percutaneous coronary intervention (PCI) is dictated by an anatomically appropriate culprit stenosis. *Patients with cardiogenic shock or severe heart failure initially seen at a non\u2013PCI-capable hospital should be transferred for cardiac catheterization and revascularization as soon as possible, irrespective of time delay from myocardial infarction (MI) onset (Class I, LOE: B). \u2020Angiography and revascularization should not be performed within the first 2 to 3 hours after administration of fibrinolytic therapy. CABG, coronary artery bypass graft; DIDO, door-in\u2013door-out; FMC, first medical contact; LOE, level of evidence; STEMI, ST-elevation myocardial infarction. (Adapted with permission from P O\u2019Gara et al: Circulation 127:e362, 2013.) relative contraindications to beta blockade (PR interval greater than 0.24"
        },
        {
            "id": "Pharmacology_Katzung_1232",
            "title": "Pharmacology_Katzung",
            "content": "Prophylaxis of angina Oral, duration 6\u20138 h \u2022 Toxicity: QT interval prolongation (but no increase of torsades de pointes), nausea, constipation, dizziness \u2022 Interactions: Inhibitors of CYP3A increase ranolazine concentration and duration of action Ivabradine: Inhibitor of sinoatrial pacemaker; reduction of heart rate reduces oxygen demand Trimetazidine, allopurinol, perhexiline, fasudil: See text Amsterdam EA et al: 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354. Borer JS: Clinical effect of \u2018pure\u2019 heart rate slowing with a prototype If inhibitor: Placebo-controlled experience with ivabradine. Adv Cardiol 2006;43:54. Burashnikov A et al: Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail 2014;7:627."
        },
        {
            "id": "Pharmacology_Katzung_1206",
            "title": "Pharmacology_Katzung",
            "content": "In patients with unstable angina, immediate-release short-acting calcium channel blockers can increase the risk of adverse cardiac events and therefore are contraindicated (see Toxicity, above). However, in patients with non\u2013Q-wave myocardial infarction, diltiazem can decrease the frequency of postinfarction angina and may be used."
        },
        {
            "id": "Pharmacology_Katzung_1219",
            "title": "Pharmacology_Katzung",
            "content": "Specific pharmacologic therapy to prevent myocardial infarction and death consists of antiplatelet agents (aspirin, ADP receptor blockers, Chapter 34) and lipid-lowering agents, especially statins (Chapter 35). Aggressive therapy with statins has been shown to reduce the incidence and severity of ischemia in patients during exercise testing and the incidence of cardiac events (including infarction and death) in clinical trials. ACE inhibitors also reduce the risk of adverse cardiac events in patients at high risk for CAD, although they have not been consistently shown to exert antianginal effects. In patients with unstable angina and non-ST-segment elevation myocardial infarction, aggressive therapy consisting of coronary stenting, antilipid drugs, heparin, and antiplatelet agents is recommended."
        },
        {
            "id": "InternalMed_Harrison_19206",
            "title": "InternalMed_Harrison",
            "content": "HMG-CoA reductase inhibitors (statins), such as atorvastatin 80 mg/d, prior to percutaneous coronary intervention (PCI), and continued thereafter, has been shown to reduce complications of the procedure and recurrences of ACS."
        },
        {
            "id": "Pharmacology_Katzung_1217",
            "title": "Pharmacology_Katzung",
            "content": "Therapy of coronary artery disease (CAD) is important because angina and other manifestations of CAD severely impact quality of life and even life itself. Several grading systems have been devised to rate the severity of disease based on the limitation of the patient\u2019s physical activity and to guide therapy (see Goldman reference). Treatment includes both medical and surgical methods. Refractory angina and acute coronary syndromes are best treated with physical revascularization, ie, percutaneous coronary intervention (PCI), with insertion of stents, or coronary artery bypass grafting (CABG). The standard of care for acute coronary syndrome (ACS) is urgent stenting. However, prevention of ACS and treatment of chronic angina can be accomplished in many patients with medical therapy."
        },
        {
            "id": "Surgery_Schwartz_1045",
            "title": "Surgery_Schwartz",
            "content": "outcome in patients with acute MI. Prevention of infarct extension is a critical component. Large segments of nonfunctional but viable myocardium contribute to the development of cardiogenic shock after MI. In the setting of acute MI, expeditious restoration of cardiac output is mandatory to minimize mortality; the extent of myocardial salvage possible decreases exponentially with increased time to restoration of coronary blood flow. The degree of coronary flow after percuta-neous transluminal coronary angioplasty correlates with inhos-pital mortality (i.e., 33% mortality with complete reperfusion, 50% mortality with incomplete reperfusion, and 85% mortality with absent reperfusion).106 Inadequate cardiac function can be a direct result of cardiac injury, including profound myocardial contusion, blunt cardiac valvular injury, or direct myocardial damage (Table 5-8).105-108 The pathophysiology of cardiogenic shock involves a vicious cycle of myocardial ischemia that causes myocardial"
        },
        {
            "id": "InternalMed_Harrison_19282",
            "title": "InternalMed_Harrison",
            "content": "Unlike beta blockers, calcium antagonists are of little value in the acute setting, and there is evidence that short-acting dihydropyridines may be associated with an increased mortality risk. The primary tool for screening patients and making triage decisions is the initial 12-lead ECG. When ST-segment elevation of at least 2 mm in two contiguous precordial leads and 1 mm in two adjacent limb leads is present, a patient should be considered a candidate for reperfusion therapy (Fig. 295-4). The process of selecting patients for fibrinolysis versus primary PCI (angioplasty or stenting; Chap. 296e) is discussed below. In the absence of ST-segment elevation, fibrinolysis is not helpful, and evidence exists suggesting that it may be harmful."
        },
        {
            "id": "InternalMed_Harrison_19161",
            "title": "InternalMed_Harrison",
            "content": "outcomes in patients with unstable angina or when used early in the course of myocardial infarction with and without cardiogenic shock. However, in patients with stable exertional angina, clinical trials have confirmed that PCI does not reduce the occurrence of death or myocardial infarction compared to optimum medical therapy. PCI can be used to treat stenoses in native coronary arteries as well as in bypass grafts in patients who have recurrent angina after CABG."
        },
        {
            "id": "InternalMed_Harrison_19204",
            "title": "InternalMed_Harrison",
            "content": "Risk ratio 1.0 1.8 3.5 3.9 6.2 7.8 95% confidence \u2013 0.5\u20136.7 1.2\u201310.6 1.3\u201311.7 1.7\u201322.3 2.6\u201323.0 FIGURE 294-4 A. Death (D), myocardial infarction (MI), or need for urgent revascularization (UR) through 6 weeks by Thrombolysis in Myocardial Infarction (TIMI) Risk Score in the unfractionated heparin arm of the TIMI 11B trial. (From EM Antman et al: JAMA 284:835, 2000.) B. Mortality rate at 42 days by baseline cardiac troponin I levels in the TIMI 3B trial. (From EM Antman et al: N Engl J Med 335:1342, 1996.) <100 mmHg, or the dose reaches 200 \u03bcg/min. Topical or oral nitrates (Chap. 293) can be used when the pain has resolved, or they may replace intravenous nitroglycerin when the patient has been pain-free for 12\u201324 h. The only absolute contraindications to the use of nitrates are hypotension or the use of sildenafil or other phosphodiesterase-5 inhibitors within the previous 24\u201348 h."
        },
        {
            "id": "InternalMed_Harrison_17832",
            "title": "InternalMed_Harrison",
            "content": "agents promote an osmotic diuresis, to avoid strenuous activity, and to observe the vascular access site for signs of complications. Overnight hospitalization may be required for high-risk patients with significant comorbidities, patients with complications occurring during the catheterization, or patients who have undergone a percutaneous coronary intervention. Hypotension early after the procedure may be due to inadequate fluid replacement or retroperitoneal bleeding from the access site. Patients who received >2 Gy of radiation during the procedure should be examined for signs of erythema. For patients who received higher doses (>5 Gy), clinical follow-up within 1 month to assess for skin injury is recommended."
        },
        {
            "id": "Surgery_Schwartz_6054",
            "title": "Surgery_Schwartz",
            "content": "cardiac mor-bidity and mortality. In nearly half of patients, thallium imaging proves to be unnecessary because cardiac risk can be predicted by clinical information alone.6 Even with coronary angiography, it is difficult to relate anatomic findings to functional signifi-cance and, hence, surgical risk. There are no data confirming that percutaneous coronary interventions or surgical revascu-larization prior to vascular surgical procedures impact mortality or incidence of myocardial infarctions. In fact, coronary angi-ography is associated with its own inherent risks, and patients undergoing coronary artery bypass grafting or coronary percuta-neous transluminal angioplasty (PTA) before needed aortoiliac reconstructions are subjected to the risks and complications of both procedures.The Coronary Artery Revascularization Prophylaxis (CARP) trial showed that coronary revascularization in patients with peripheral vascular disease and significant coronary artery disease, who are considered"
        },
        {
            "id": "Pharmacology_Katzung_1179",
            "title": "Pharmacology_Katzung",
            "content": "Nicorandil is a nicotinamide nitrate ester that has vasodilating properties in normal coronary arteries but more complex effects in patients with angina. Recent studies in isolated myocytes indicate that the drug activates an Na+/Ca2+ exchanger and reduces intracellular Ca2+ overload. Clinical studies suggest that it reduces both preload and afterload. It also provides some myocardial protection via preconditioning by activation of cardiac KATP channels. One large trial showed a significant reduction in relative risk of fatal and nonfatal coronary events in patients receiving the drug. Nicorandil is currently approved for use in the treatment of angina in Europe and Japan but has not been approved in the USA. Molsidomine is a prodrug that is converted to a nitric oxide\u2013releasing metabolite. It is said to have efficacy comparable to that of the organic nitrates and is not subject to tolerance. Recent studies suggest that it may reduce cerebral vasospasm in stroke. It is not available"
        },
        {
            "id": "InternalMed_Harrison_19418",
            "title": "InternalMed_Harrison",
            "content": "E. Stent placement with excellent angiographic result. (From A Al Mahameed, DL Bhatt: Cleve Clin J Med 73:S45, 2006; with permission.) Atlas of Percutaneous Revascularization Jane A. Leopold, Deepak L. Bhatt, David P. Faxon Percutaneous coronary intervention (PCI) is the most widely employed coronary revascularization procedure worldwide (Chap. 296e). It 297e is now applied to patients with stable angina; patients with acute coronary syndromes, including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI); and as a primary treatment strategy in patients with ST-segment elevation myocardial infarction (STEMI). PCI is also applicable to patients with either single-vessel or multivessel disease."
        },
        {
            "id": "InternalMed_Harrison_9355",
            "title": "InternalMed_Harrison",
            "content": "Cangrelor An adenosine analogue, cangrelor binds reversibly to P2Y12 and inhibits its activity. The drug has a half-life of 3\u20136 min and is given IV as a bolus followed by an infusion. When stopped, platelet function recovers within 60 min. A trial comparing cangrelor with placebo during percutaneous coronary interventions and a study comparing cangrelor with clopidogrel after such procedures revealed little or no advantage of cangrelor. A third trial compared cangrelor (given as an IV bolus of 30 \u03bcg/kg followed by an infusion of 4 \u03bcg/kg per minute for at least 2 h, or for the duration of the procedure, whichever was longer) with a loading dose of clopidogrel (300 or 600 mg) in 11,145 patients undergoing urgent or elective percutaneous coronary intervention. The rate of the primary efficacy endpoint, a composite of death, MI, ischemia-driven revascularization, and stent thrombosis, was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (p = .005). The rates of severe"
        },
        {
            "id": "InternalMed_Harrison_19219",
            "title": "InternalMed_Harrison",
            "content": "Class I (Level of Evidence: A) Indications Recurrent angina at rest/low-level activity despite treatment Elevated TnT or TnI New ST-segment depression CHF symptoms, rales, MR EF <0.40 Sustained VT PCI <6 months, prior CABG High-risk findings from noninvasive testing Hemodynamic instability Mild-to-moderate renal dysfunction Diabetes mellitus High TIMI Risk Score (>3)b aAny one of the high-risk indicators. bSee Antman (JAMA 284:835, 2000). Abbreviations: CABG, coronary artery bypass grafting; CHF, congestive heart failure; EF, ejection fraction; MR, mitral regurgitation; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; TnI, troponin I; TnT, troponin T; VT, ventricular tachycardia. Source: Modified from J Anderson et al: J Am Coll Cardiol 61:e179, 2013."
        },
        {
            "id": "InternalMed_Harrison_28053",
            "title": "InternalMed_Harrison",
            "content": "In general, the treatment of coronary disease is not different in the diabetic individual (Chap. 293). Revascularization procedures for CHD, including percutaneous coronary interventions (PCI) and coronary artery bypass grafting (CABG), may be less efficacious in the diabetic individual. Initial success rates of PCI in diabetic individuals are similar to those in the nondiabetic population, but diabetic patients have higher rates of restenosis and lower long-term patency and survival rates in older studies. Aggressive cardiovascular risk modification in all individuals with DM and glycemic control should be individualized, as discussed in Chap. 418. In patients with known CHD and type 2 DM, an ACE inhibitor (or ARB), a statin, and acetylsalicylic acid (ASA; aspirin) should be considered. Past trepidation about using beta blockers in individuals who have diabetes should not prevent use of these agents because they clearly benefit diabetic patients after MI. In"
        },
        {
            "id": "Surgery_Schwartz_1057",
            "title": "Surgery_Schwartz",
            "content": "with acute MI, its role in cardiogenic shock is less clear. Patients in car-diac failure from an acute MI may benefit from pharmaco-logic or mechanical circulatory support in a manner similar to that of patients with cardiac failure related to blunt cardiac Brunicardi_Ch05_p0131-p0156.indd 14929/01/19 11:06 AM 150BASIC CONSIDERATIONSPART Iinjury. Additional pharmacologic tools may include the use of \u03b2-blockers to control heart rate and myocardial O2 consumption, nitrates to promote coronary blood flow through vasodilation, and ACE inhibitors to reduce ACE-mediated vasoconstrictive effects that increase myocardial workload and myocardial O2 consumption.Current guidelines of the American Heart Association recommend percutaneous transluminal coronary angiography for patients with cardiogenic shock, ST elevation, left bundle-branch block, and age less than 75 years.111,112 Early definition of coronary anatomy and revascularization is the pivotal step in treatment of patients with"
        },
        {
            "id": "InternalMed_Harrison_629",
            "title": "InternalMed_Harrison",
            "content": "soon before noncardiac surgery may increase the risk of bleeding during surgery if dual antiplatelet therapy (aspirin and thienopyridine) is administered; moreover, stent placement shortly before noncardiac surgery increases the perioperative risk of MI and cardiac death due to stent thrombosis if such therapy is withdrawn prematurely (Chap. 296e). It is recommended that, if possible, noncardiac surgery be delayed 30\u201345 days after placement of a bare metal coronary stent and for 365 days after a drug-eluting stent. For patients who must undergo noncardiac surgery early (>14 days) after PCI, balloon angioplasty without stent placement appears to be a reasonable alternative because dual antiplatelet therapy is not necessary in such patients. One recent clinical trial further suggests that after 6 months, bare metal and drug eluting stents may not pose a threat."
        },
        {
            "id": "InternalMed_Harrison_19317",
            "title": "InternalMed_Harrison",
            "content": "Favorable effects on the ischemic process and ventricular remodeling (see below) previously led many physicians to routinely use intravenous nitroglycerin (5\u201310 \u03bcg/min initial dose and up to 200 \u03bcg/min as long as hemodynamic stability is maintained) for the first 24\u201348 h after the onset of infarction. However, the benefits of routine use of intravenous nitroglycerin are less in the contemporary era where betaadrenoceptor blockers and ACE inhibitors are routinely prescribed for patients with STEMI. Results of multiple trials of different calcium antagonists have failed to establish a role for these agents in the treatment of most patients with STEMI. Therefore, the routine use of calcium antagonists cannot be recommended. Strict control of blood glucose in diabetic patients with STEMI has been shown to reduce the mortality rate. Serum magnesium should be measured in all patients on admission, and any demonstrated deficits should be corrected to minimize the risk of arrhythmias."
        },
        {
            "id": "InternalMed_Harrison_19359",
            "title": "InternalMed_Harrison",
            "content": "Various secondary preventive measures are at least partly responsible for the improvement in the long-term mortality and morbidity rates after STEMI. Long-term treatment with an antiplatelet agent (usually aspirin) after STEMI is associated with a 25% reduction in the risk of recurrent infarction, stroke, or cardiovascular mortality (36 fewer events for every 1000 patients treated). An alternative antiplatelet agent that may be used for secondary prevention in patients intolerant of aspirin is clopidogrel (75 mg orally daily). ACE inhibitors or ARBs and, in appropriate patients, aldosterone antagonists should be used indefinitely by patients with clinically evident heart failure, a moderate decrease in global ejection fraction, or a large regional wall motion abnormality to prevent late ventricular remodeling and recurrent ischemic events."
        },
        {
            "id": "InternalMed_Harrison_9394",
            "title": "InternalMed_Harrison",
            "content": "Fondaparinux is used at a dose of 2.5 mg once daily in patients with acute coronary syndromes. When this prophylactic dose of fondaparinux was compared with treatment doses of enoxaparin in patients with non-ST-segment elevation acute coronary syndrome, there was no difference in the rate of cardiovascular death, MI, or stroke at 9 days. However, the rate of major bleeding was 50% lower with fondaparinux than with enoxaparin, a difference that likely reflects the fact that the dose of fondaparinux was lower than that of enoxaparin. In acute coronary syndrome patients who require percutaneous coronary intervention, there is a risk of catheter thrombosis with fondaparinux unless adjunctive heparin is given."
        },
        {
            "id": "Pharmacology_Katzung_1210",
            "title": "Pharmacology_Katzung",
            "content": "Because of the high prevalence of angina, new drugs are actively sought for its treatment. Some of the drugs or drug groups currently under investigation are listed in Table 12\u20136. Ranolazine appears to act by reducing a late sodium current (INa) that facilitates calcium entry via the sodium-calcium exchanger (see Chapter 13). The reduction in intracellular calcium concentration that results from ranolazine reduces diastolic tension, cardiac contractility, and work. Ranolazine is approved for use in angina in the USA. Several studies demonstrate its effectiveness in stable angina, but it does not reduce the incidence of death in acute coronary syndromes. Ranolazine prolongs the QT interval in patients with coronary artery disease (but shortens it in patients with long QT syndrome, LQT3). It has not been associated with torsades de pointes arrhythmia and may inhibit the metabolism of digoxin and simvastatin."
        },
        {
            "id": "InternalMed_Harrison_625",
            "title": "InternalMed_Harrison",
            "content": "History of myocardial infarction Current angina considered to be ischemic Requirement for sublingual nitroglycerin Positive exercise test Pathological Q-waves on ECG History of PCI and/or CABG with current angina considered to be ischemic Left ventricular failure by physical examination History of paroxysmal nocturnal dyspnea History of pulmonary edema S3 gallop on cardiac auscultation Bilateral rales on pulmonary auscultation Pulmonary edema on chest x-ray History of transient ischemic attack History of cerebrovascular accident Treatment with insulin Abbreviations: CABG, coronary artery bypass grafting; ECG, electrocardiogram; PCI, percutaneous coronary interventions. Source: Adapted from TH Lee et al: Circulation 100:1043, 1999."
        },
        {
            "id": "InternalMed_Harrison_19141",
            "title": "InternalMed_Harrison",
            "content": "\u03b2-Adrenergic Blockers These drugs represent an important component of the pharmacologic treatment of angina pectoris (Table 293-5). They reduce myocardial oxygen demand by inhibiting the increases in heart rate, arterial pressure, and myocardial contractility caused by adrenergic activation. Beta blockade reduces these variables most strikingly during exercise but causes only small reductions at rest. Long-acting beta-blocking drugs or sustained-release formulations offer the advantage of once-daily dosing (Table 293-5). The therapeutic aims include relief of angina and ischemia. These drugs also can reduce mortality and reinfarction rates in patients after myocardial infarction and are moderately effective antihypertensive agents."
        },
        {
            "id": "Pharmacology_Katzung_4285",
            "title": "Pharmacology_Katzung",
            "content": "Special Problems in Management of Hypothyroidism A. Myxedema and Coronary Artery Disease Since myxedema frequently occurs in older persons, it is often associated with underlying coronary artery disease. In this situation, the low levels of circulating thyroid hormone actually protect the heart against increasing demands that could result in angina pectoris, atrial fibrillation, or myocardial infarction. Correction of myxedema must be done cautiously to avoid provoking these cardiac events. If coronary artery surgery is indicated, it should be done first, prior to correction of the myxedema by thyroxine administration. B. Myxedema Coma Myxedema coma is an end state of untreated hypothyroidism. It is associated with progressive weakness, stupor, hypothermia, hypoventilation, hypoglycemia, hyponatremia, water intoxication, shock, and death."
        },
        {
            "id": "InternalMed_Harrison_19164",
            "title": "InternalMed_Harrison",
            "content": "It is usual clinical practice to administer aspirin indefinitely and a P2Y12 antagonist for 1\u20133 months after the implantation of a bare metal stent. Although aspirin in combination with a thienopyridine may help prevent coronary thrombosis during and shortly after PCI with stenting, there is no evidence that these medications reduce the incidence of restenosis."
        },
        {
            "id": "InternalMed_Harrison_19314",
            "title": "InternalMed_Harrison",
            "content": "ACE inhibitors reduce the mortality rate after STEMI, and the mortality benefits are additive to those achieved with aspirin and beta blockers. The maximum benefit is seen in high-risk patients (those who are elderly or who have an anterior infarction, a prior infarction, and/or globally depressed LV function), but evidence suggests that a short-term benefit occurs when ACE inhibitors are prescribed unselectively to all hemodynamically stable patients with STEMI (i.e., those with a systolic pressure >100 mmHg). The mechanism involves a reduction in ventricular remodeling after infarction (see \u201cVentricular Dysfunction\u201d later) with a subsequent reduction in the risk of CHF. The rate of recurrent infarction may also be lower in patients treated chronically with ACE inhibitors after infarction."
        }
    ],
    "scores": [
        0.03311363324732309,
        0.02785857348795081,
        0.027646761769200175,
        0.027578701964596216,
        0.026114255474898613,
        0.025875547217010637,
        0.0249694243894741,
        0.023633447718336573,
        0.021945616094852953,
        0.021135289029234658,
        0.020208070617906686,
        0.018812930577636458,
        0.018251356486650605,
        0.01819535191464726,
        0.01774915573706118,
        0.01683644595359366,
        0.01672194582642344,
        0.016560678325384208,
        0.016547008547008548,
        0.01632680261228842,
        0.016083916083916083,
        0.01601640079441348,
        0.015783259802398558,
        0.015753259295026557,
        0.0156981039152918,
        0.01562592482983131,
        0.015597605948854362,
        0.015592203898050975,
        0.015592203898050975,
        0.015463337831758885,
        0.015432098765432098,
        0.015008068854222699
    ]
}